|Last Update: 05/17/13 - 4:01 PM EDT|
|YTD Performance: 21.50%|
|Previous Close: $49.64|
|52 Week Range: $35.67 - $50.17|
|Oustanding Shares: 1,013,805,980|
|Market Cap: 50,325,328,847|
|Qtr (04/13)||Qtr (07/13)||FY (04/13)||FY (04/14)|
|Number of Analysts||16||14||17||17|
|Growth Rate (Year over Year)||4.29%||5.63%||6.61%||3.67%|
MDT was downgraded from Outperform to Neutral, Credit Suisse said. Valuation call, based on a $53 price target.
Two domestic exploration and production names that scream 'buy me' are Devon and Southwestern.
MDT estimates were raised through 2015, BMO Capital said. Company continues to grow across the board. Outperform rating and new $52 price target.
MDT was downgraded to Neutral, Lazard Capital Markets said. Stock is up 30% over the past 8 months and the company lacks near-term catalysts.
MDT was downgraded from Buy to Hold, Wunderlich said. Valuation call, as the stock is up 13% year-to-date.
MDT was upgraded from Neutral to Outperform Credit Suisse said. $50 price target. Company can grow faster than consensus expectations over the coming quarters.
JPMorgan Global Healthcare Conference (Day 2 of 5) - 01/06/13 - 01/10/13 San Francisco, CA
MDT was upgraded from Neutral to Buy, Mizuho said. $49 price target. Spine business should grow through new products and insurance expansion.
Portfolio Mgr. David Peltier analyzes a low-dollar stock on the verge of a potential turnaround.